Geographic Atrophy Clinical Trial Monitor — Dry AMD Complement & Cell Therapy Programs 2026

The geographic atrophy trial landscape in 2026

Geographic atrophy (GA) — the advanced form of dry age-related macular degeneration — is the fastest-growing high-value ophthalmic indication in drug development. With no approved therapies until 2023, the field had accumulated decades of unmet need. Now, with two complement inhibitors approved and a rich pipeline expanding beyond complement inhibition, the GA landscape is one of the most active and commercially significant in ophthalmology.

The ~1 million US GA patients with no good treatment options drove sustained development pressure. As of early 2026, there are 27+ active trials spanning complement inhibition, RPE cell replacement, visual cycle modulation, and neuroprotective approaches. For ophthalmology BD teams, this density of competing mechanisms demands systematic, daily monitoring.

Approved therapies: Syfovre and Izervay

Two complement inhibitors received FDA approval in 2023, creating the first-ever treatment options for GA patients:

Syfovre (pegcetacoplan, Apellis Pharmaceuticals) — approved February 2023

Pegcetacoplan is a C3 complement inhibitor delivered as an intravitreal injection monthly or every other month. The DERBY and OAKS Phase 3 trials showed approximately 22% reduction in GA growth rate at 24 months with monthly dosing. Apellis has since initiated post-approval real-world studies (NCT06161584) to generate durability and comparative effectiveness data.

Izervay (avacincaptad pegol, Astellas/Iveric Bio) — approved August 2023

Avacincaptad pegol is a C5 complement inhibitor (versus Syfovre's C3 inhibition) administered as a monthly intravitreal injection. The GATHER1 and GATHER2 Phase 3 trials demonstrated ~14-35% reduction in GA growth. Astellas acquired Iveric Bio in 2023 and is now running real-world studies and ASP3021 Phase 4 programs (NCT06779773).

Key mechanisms generating new GA trials

Complement inhibition: beyond C3 and C5

The approval of two complement inhibitors validated the pathway, but questions remain about optimal complement node targeting. New programs are exploring:

• Subcutaneous delivery: Regeneron's pozelimab (anti-C5) combined with cemdisiran (RNAi targeting complement component C5) in a Phase 3 program (NCT06541704) — potentially enabling subcutaneous administration rather than intravitreal injection, a meaningful differentiator for patient acceptance
• Factor D and Factor B inhibitors: Alternative complement pathway nodes being explored in early-stage programs
• Dual complement blockade: Combination approaches targeting multiple nodes for additive efficacy

Visual cycle modulation

Belite Bio's tinlarebant (Phase 3, NCT05949593) targets retinol-binding protein 4 (RBP4) — the protein responsible for delivering vitamin A to the retina. By reducing the accumulation of toxic vitamin A dimers (bisretinoids) that contribute to RPE cell death, this oral approach addresses a distinct upstream mechanism from complement inhibition.

RPE cell replacement therapy

Genentech's Opregen program (Phase 2, NCT05626114) uses stem cell-derived retinal pigment epithelium (RPE) cells delivered via subretinal injection. This approach aims to replace lost RPE cells in GA rather than slow their destruction — a potential disease-modifying rather than disease-slowing strategy.

Neuroprotection and anti-apoptotic approaches

Boehringer Ingelheim has two active Phase 2 GA programs — BI 771716 and BI 1584862 — exploring distinct mechanisms. Both are in active accrual, representing significant investment in a competitive space from a company with no currently approved ophthalmic product.

Phase 3 spotlight: key geographic atrophy trials

NCT ID	Sponsor	Drug / Intervention	Phase	Mechanism	Status
NCT06541704	Regeneron	Pozelimab + cemdisiran (SC delivery)	Phase 3	Complement C5 + RNAi	Recruiting
NCT05949593	Belite Bio	Tinlarebant (oral)	Phase 3	Visual cycle / RBP4 inhibition	Recruiting
NCT06161584	Apellis Pharmaceuticals	Pegcetacoplan (Syfovre) — post-approval RWE	Phase 4 / RWE	Complement C3 inhibition	Active
NCT06779773	Astellas	Avacincaptad pegol (Izervay) — real-world study	Phase 4	Complement C5 inhibition	Active
NCT05626114	Roche / Genentech	Opregen — subretinal RPE cell therapy	Phase 2	RPE cell replacement	Recruiting
Active (Phase 2)	Boehringer Ingelheim	BI 771716 (Phase 2)	Phase 2	Undisclosed / novel	Recruiting
Active (Phase 2)	Boehringer Ingelheim	BI 1584862 (Phase 2)	Phase 2	Undisclosed / novel	Recruiting

Top sponsors in geographic atrophy

• Apellis Pharmaceuticals — Syfovre (pegcetacoplan) approved Feb 2023; post-approval RWE studies; portfolio leader in GA.
• Astellas — Acquired Iveric Bio in 2023; Izervay (avacincaptad) approved Aug 2023; Phase 4 real-world program active.
• Regeneron — Phase 3 combination program (pozelimab + cemdisiran) targeting subcutaneous delivery as a key differentiator from intravitreal competitors.
• Boehringer Ingelheim — Two Phase 2 GA programs; significant portfolio investment with no ophthalmic product yet.
• Roche / Genentech — Opregen cell therapy (Phase 2); distinct approach targeting RPE replacement rather than disease slowing.
• Belite Bio — Tinlarebant (Phase 3); oral RBP4 inhibitor offering a non-injection alternative for GA patients.

Why monitoring GA trials matters for ophthalmology BD teams

Geographic atrophy represents an unusual competitive dynamics situation: two approved therapies but continued heavy investment from large pharma because neither currently approved drug restores vision — they only slow progression. This creates sustained commercial pressure for the next wave of differentiated therapies.

Key competitive intelligence events to monitor in GA:

• Regeneron Phase 3 enrollment progress: A subcutaneous complement inhibitor combination, if it succeeds, could dramatically change the intravitreal injection competitive landscape.
• Real-world Syfovre vs. Izervay comparative data: Post-approval studies from Apellis and Astellas will generate head-to-head surrogate data that affects prescriber and payer positioning.
• Boehringer Ingelheim Phase 2 readouts: Two programs with undisclosed mechanisms; Phase 2 data will reveal whether BI is pursuing acquisitions or internal development for Phase 3.
• Opregen Phase 2 data from Genentech: RPE cell replacement is the only approach that could restore rather than preserve vision — positive data would reframe the entire GA treatment paradigm.
• Tinlarebant Phase 3 enrollment: An oral drug in GA would address a significant patient and prescriber preference unmet need compared to monthly injections.

DataLookout tracks all these programs daily and delivers field-level change alerts for enrollment status, protocol amendments, sponsor changes, and new trial registrations.

Related ophthalmology and retinal disease trial monitors

• Rare disease clinical trials — including rare retinal dystrophies, Stargardt disease, and inherited retinal conditions
• Diabetes clinical trials — diabetic macular edema and diabetic retinopathy programs overlap with retinal vascular biology